A post by @FirstSquawk on X.
NOVO NORDISK CEO SAYS WEGOVY PILL SALES INCREASED 20% IN THE US IN Q3; "I THINK THERE IS NO SECRET T…
@FirstSquawk on X
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Novo Nordisk CEO said U.S. sales of the Wegovy pill rose 20% in the third quarter. The executive also acknowledged that the growth curve for the obesity drug has flattened. The disclosure offers a mixed signal for the Danish drugmaker, pairing sequential gains in the oral formulation with signs that overall momentum is cooling. Investors will watch whether the pill can offset slower growth in the broader Wegovy franchise.
Muhabbit's AI wrote this summary of @FirstSquawk's post in its own words. It can get details wrong, so read the post on X.
Named in this story
Novo Nordisk (NVO), Wegovy, CEO
A linked name opens that asset's sentiment page.